Inventor · disambiguated record
Georg H. Wätzig
Also filed as: WAETZIG GEORG · WAETZIG GEORG H · WATZIG GEORG H · WÄTZIG GEORG
9 granted patents·7 pending applications·59 citations·filing 2004–2023
86Inventor score
Top patents by PatentIndex Score
16 records- 0192US9573989B2Sgp130/Fc dimersCONARIS RES INST AG·Filed 2015·Granted Feb 21, 2017·18 cites·5 claims
- 0285US7629147B2PEGylated soluble GP130-dimers useful as a medicamentCONARIS RES INST AG·Filed 2008·Granted Dec 8, 2009·11 cites·4 claims
- 0383US9034817B2sgp130/Fc dimers for treatment of inflammatory diseaseCONARIS RES INST AG·Filed 2013·Granted May 19, 2015·6 cites·9 claims
- 0482US8895012B2sgp130/Fc dimersWÄTZIG GEORG H·Filed 2007·Granted Nov 25, 2014·9 cites·12 claims
- 0579US7534862B2PEGylated soluble gp130-dimers useful as a medicamentCONARIS RES INST AG·Filed 2004·Granted May 19, 2009·14 cites·7 claims
- 0674US10758552B2Pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammationCONARIS RES INSTITUTE AG·Filed 2014·Granted Sep 1, 2020·1 cites·14 claims
- 0771US2025268885A1Oral composition comprising nicotinamideCONARIS RES INSTITUTE AG·Filed 2023·Application pending·0 cites
- 0860US2025213549A1Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseasesCONARIS RES INSTITUTE AG·Filed 2023·Application pending·0 cites
- 0954US10888555B2Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiotaCONARIS RES INSTITUTE AG·Filed 2014·Granted Jan 12, 2021·0 cites·30 claims
- 1054US2023414599A1Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infectionsCONARIS RES INSTITUTE AG·Filed 2021·Application pending·0 cites
- 1153US2023235020A1Pharmaceutical compound for the treatment of atherosclerotic cardiovascular diseaseFERRING BV·Filed 2021·Application pending·0 cites
- 1248US8501696B2Soluble GP130 muteins with improved binding activityGROETZINGER JOACHIM·Filed 2008·Granted Aug 6, 2013·0 cites·24 claims
- 1342US2021275513A1Shellac microcapsule formulations and compositions for topical intestinal delivery of vitamin b3CONARIS RES INSTITUTE AG·Filed 2017·Application pending·0 cites
- 1442US2019105278A1Shellac microcapsule formulations and compositionsCONARIS RES INSTITUTE AG·Filed 2017·Application pending·0 cites
- 1541US2014072984A1Soluble gp130 muteins with improved binding activityCONARIS RES INST AG·Filed 2013·Application pending·0 cites
- 1639US8206948B2Optimized nucleotide sequences encoding sgp130SEEGERT DIRK·Filed 2005·Granted Jun 26, 2012·0 cites·9 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →